ESC 2025: pooled MACE results across the obicetrapib programme (Stephen Nicholls)

Stephen Nicholls presents pooled major adverse cardiovascular event data from the obicetrapib phase 3 programme at ESC 2025. Pooled event counts from trials powered for LDL-C are hypothesis-generating, not an outcomes result: PREVAIL remains the trial that answers the question.